Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: Tardive dyskinesia is not associated with supersensitive psychosis

Schizophrenia Research

Volumn 63, Issue 1-2, 2003, Pages 151-160

  Apud, Jose A ^a,b   Egan, Michael F ^a   Wyatt, Richard J ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b Clinical Brain Disorders Branch   (United States)

Author keywords

Antipsychotic; Coded inactive medication; Drug withdrawal; Neuroleptics; Schizophrenia; Tardive dyskinesia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; RISK FACTOR; SCHIZOPHRENIA; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

EID: 0041706321     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00338-9     Document Type: Article

References (42)

1. Albus M., Naber D., Muller-Spahn F., Douillet P., Reinertshofer T., Ackenheil M. Tardive dyskinesia: relation to computer-tomographic, endocrine, and psychopathological variables. Biol. Psychiatry. 20:1985;1082-1089.
2. Diagnostic and Statistical Manual of Mental Disorders. 2nd ed. 1980;American Psychiatric Association, Washington, DC.
3. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. 1987;American Psychiatric Association, Washington, DC. revised.
4. Andreassen O.A., Jorgensen H. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol. 61:2000;525-541.
5. Andrews P., Hall J.N., Snaith R.P. A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. Br. J. Psychiatry. 128:1976;451-455.
6. Apud J.A., Egan M.F., Wyatt R.J. Effects of smoking during antipsychotic withdrawal in patients with chronic schizophrenia. Schizophr. Res. 46:2000;119-127.
7. Baldessarini R.J., Tarsy D. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Annu. Rev. Neurosci. 3:1980;23-41.
8. Bartko J.J. The intra-class correlation coefficient as a measure of reliability. Psychol. Rep. 19:1966;3-11.
9. Bigelow L.B., Berthot B.D. The psychiatric symptom assessment scale (PSAS). Psychopharmacol. Bull. 25:1989;168-173.
10. Brown W.A., Laughren T. Low serum prolactin and early relapse following neuroleptic withdrawal. Am. J. Psychiatry. 138:1981;237-239.
11. Buchanan R.W., Kirkpatrick B., Summerfelt A., Hanlon T.E., Levine J., Carpenter W.T. Jr. Clinical predictors of relapse following neuroleptic withdrawal. Biol. Psychiatry. 32:1992;72-78.
12. Carpenter W.T., McGlashan T.H., Strauss J.S. The treatment of acute schizophrenia without drugs: an investigation of some current assumptions. Am. J. Psychiatry. 134:1977;14-20.
13. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr. Res. 5:1991;21-33.
14. Chouinard G., Jones B.D. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am. J. Psychiatry. 137:1980;16-21.
15. Chouinard G., Sultan S. Treatment of supersensitivity psychosis with antiepileptic drugs: report of a series of 43 cases. Psychopharmacol. Bull. 26:1990;337-341.
16. Chouinard G., Jones B.D., Annable L. Neuroleptic-induced supersensitivity psychosis. Am. J. Psychiatry. 135:1978;1409-1410.
17. Clow A., Theodorou A., Jenner P., Marsden C.D. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration. Eur. J. Pharmacol. 63:1980;135-144.
18. Crane G.E. Pseudoparkinsonism and tardive dyskinesia. Arch. Neurol. 27:1972;426-430.
19. Davis K.L., Rosenberg G.S. Is there a limbic system equivalent of tardive dyskinesia? Biol. Psychiatry. 14:1979;699-703.
20. Dixon L., Thaker G., Conley R., Ross D., Cascella N., Tamminga C. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophr. Res. 10:1993;267-271.
21. Egan M.F., Apud J., Wyatt R.J. Treatment of tardive dyskinesia. Schizophr. Bull. 23:1997;583-609.
22. Galili-Mosberg R., Gil-Ad I., Weizman A., Melamed E., Offen D. Haloperidol-induced neurotoxicity: possible implications for tardive dyskinesia. J. Neural Transm. 107:2000;479-490.
23. Hogarty G.E., Ulrich R.F., Mussare F. Drug discontinuance among long term, successfully maintained schizophrenic outpatients. Dis. Nerv. Syst. 37:1976;494-500.
24. Hunt J.I., Singh H., Simpson G.M. Neuroleptic-induced supersensitivity psychosis: retrospective study of schizophrenic inpatients. J. Clin. Psychiatry. 49:1988;258-261.
25. Jeste D.V., Wyatt R.J. Changing epidemiology of tardive dyskinesia: an overview. Am. J. Psychiatry. 138:1981;297-309.
26. Jeste D.V., Wyatt R.J. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity? J. Clin. Psychiatry. 42:1982;455-457.
27. Kapitany T., Meszaros K., Lenzinger E., Schindler S.D., Barnas C., Fuchs K., Sieghart W., Aschauer H.N., Kasper S. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr. Res. 32:1998;101-116.
28. Klawans H.L., Carvey P., Hitri A., Nausieda P.A., Weiner W.J. Correlation between daily dosage of chlorpromazine and subsequent supersensitivity. Adv. Biochem. Psychopharmacol. 24:1980;569-572.
29. Levinson A.J., Garside S., Rosebush P.I., Mazurek M.F. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. Neuroscience. 84:1998;201-211.
30. Lieberman J.A., Kane J.M., Sarantakos S., Gadaleta D., Woerner M., Alvir J., Ramos-Lorenzi J. Prediction of relapse in schizophrenia. Arch. Gen. Psychiatry. 44:1987;597-603.
31. Llorca P.M., Penault F., Lancon C., Dufumier E., Vaiva G. The concept of supersensitive psychosis. The particular case of clozapine. Encephale. 25:1999;638-644.
32. Llorca P.M., Vaiva G., Lancon C. Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal. Can. J. Psychiatry. 46:2001;87-88.
33. Meredith G.E., De Souza I.E.J., Tipper G., Wong M.L., Hyde T., Egan M.F. Persistent alterations in dendrites, spines, and dynorphinergic synapses of nucleus accumbens shell of rats with neuroleptic-induced dyskinesias. J. Neurosci. 20:2000;7798-7806.
34. Overall J.E., Gorham D.R. The brief psychiatry rating scale. Psychol. Rep. 10:1962;799-812.
35. Prien R.F., Cole J.O. High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health-psychopharmacology research branch collaborative study group. Arch. Gen. Psychiatry. 18:1968;482-495.
36. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry. 3:1982;486-487.
37. Seeman P. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J. Clin. Psychopharmacol. 8(4 Suppl):1988;3S-9S.
38. Singh H., Hunt J.I., Vitiello B., Simpson G.M. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. J. Clin. Psychiatry. 52:1990;90-96.
39. Weinberger D.R., Bigelow L.B., Klein S.T., Wyatt R.J. Drug withdrawal in chronic schizophrenic patients: in search of neuroleptic-induced supersensitivity psychosis. J. Clin. Psychopharmacol. 1:1981;120-123.
40. Wyatt R.J. The dopamine hypothesis: variations on a theme. Cancro R., Dean S.R. Research in the Schizophrenic Disorders: The Stanley R. Dean Award Lectures. 1985;225-247 Spectrum Publications, New York.
41. Wyatt R.J., Torgow J.S. A comparison of equivalent clinical potencies of neuroleptics as used to treat schizophrenic and affective disorders. J. Psychiatr. Res. 13:1976;91-98.
42. Zander K.J., Fischer B., Zimmer R., Ackenheil M. Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal. Psychopharmacology (Berlin). 73:1981;43-47.